Initiating therapy in Parkinson's disease^†

Potential conflicts of interest: Dr. Weiner has received research funding from Boehringer Ingelheim and GlakoSmithKline, consulting or advisory honoraria from Santhera, GlakoSmithKline, and TEVA, and speaking honorarium from Novartis. Dr Ahlskog receives no financial support from industry. Dr Factor has received research funding from TEVA Neuroscience and Schering Plough, legal fees from Boehringer Ingelheim, and speaking honoraria from TEVA. Dr Suchowersky has received research funding from Solvay Pharma. Dr Reich has received research funding from Cephalon and has served on a speaking bureau for Teva.